News und Analysen
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
EQS-News: Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
EQS-News: Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
EQS-News: Evotec SE to announce results for the first nine months 2023 on 08 November 2023
EQS-News: Evotec SE to announce results for the first nine months 2023 on 08 November 2023
EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
EQS-News: Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
EQS-News: Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
EQS-News: Evotec SE reports results for the first half-year 2023 and provides corporate updates
EQS-News: Evotec SE reports results for the first half-year 2023 and provides corporate updates
EQS-News: Evotec SE reports first half-year 2023 results on 29 August 2023
EQS-News: Evotec SE reports first half-year 2023 results on 29 August 2023
EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
EQS-News: Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
EQS-News: Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
EQS-News: Evotec provides update on financial impact of cyber-attack
EQS-News: Evotec provides update on financial impact of cyber-attack
EQS-Adhoc: Evotec provides update on financial impact of cyber-attack
EQS-Adhoc: Evotec provides update on financial impact of cyber-attack
EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
EQS-News: Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
EQS-News: Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
EQS-News: Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme
EQS-News: Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme
EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items
EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items